ArticleThrombosis journal2026
An integrative analysis of genetic factors reveals dysregulation of cytokines, immune signaling, and T cell activity as the underlying immune mechanisms in autoimmune immune thrombocytopenia.
Article in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune thrombocytopenia (ITP) is an autoimmune disorder characterized by immune-mediated platelet destruction, leading to an abnormally reduced platelet count. While numerous susceptibility genomic loci have been identified, the genetic mechanisms and pathways driving ITP remain poorly understood. This limits treatment options to broad immunosuppressants that increase patient vulnerability.
objectiveThis study aims to uncover the functional and biological significance of ITP-associated genetic variations by integrating bioinformatics approaches. It seeks to identify functional SNPs, key immune pathways, and potential drug targets to enhance understanding of ITP pathogenesis and support the development of targeted therapies.
methodsAn integrative bioinformatics approach was employed to identify expression quantitative trait loci (eQTL) and pathogenic SNPs, reconstruct protein-protein interaction (PPI) networks, perform gene ontology analysis, and explore potential drug targets.
resultsThe study identified 60 eQTL and 6 pathogenic SNPs associated with ITP, along with over 300 gene ontology processes. 14 hub genes in the PPI network were linked to key immune mechanisms, including T cell dysfunction (CD40, CTLA4, FOXP3, IL-10, IL-4, TBX21), cytokine dysregulation (IFNG, IL-6, IL-10, IL-4, TNF-α, TGFB1), JAK/STAT signaling (JAK2, STAT1, STAT3), and pattern-recognition (TLR4). TNF-α emerged as the top-ranked hub gene. Additionally, several platelet related genes (HPA2, MPL, PRKCA, PTPN11, and others) were implicated in the analysis.
conclusionFunctional SNPs and hub genes identified in this study serve as potential biomarkers for ITP diagnosis and prognosis. Cytokine pathways and T cell subsets were highlighted as central players in ITP pathogenesis. The drug-gene interaction analysis further suggests potential therapeutic avenues through drug repurposing, offering insights into novel treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.